Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple Myeloma

Video

In Partnership With:

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

Francesco Maura, MD, an assistant professor and principal investigator of the myeloma genomic lab at Sylvester Comprehensive Cancer Center, discusses the challenges of whole-genome sequencing in multiple myeloma.

The widespread adoption of whole-genome sequencing is unlikely in the United States, says Maura. The technology is expensive and difficult to standardize, Maura explains.

The Pan-Cancer Analysis of Whole Genomes Consortium of the International Cancer Genome Consortium and The Cancer Genome Atlas is working toward reaching a consensus regarding the standardization of whole-genome sequencing, Maura explains. However, these complicated guidelines will require tailoring and additional research over many years, so significant and long-term efforts are needed, Maura adds.

Another challenge of whole-genome sequencing is storage, Maura says. Whole-genome sequencing data for 3 to 4 patients requires approximately 1 terabyte of storage, so utilizing this platform for thousands of patients would require adopting a new approach to cancer genomics and data storage, concludes Maura.

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS